HGSI: Summary for Human Genome Sciences, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 3:25am EST - Canadian Markets open in 6 hours and 5 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Human Genome Sciences Inc. (HGSI)

On Nov 24: 27.92 USD 0.00 (0.00%)

MORE ON HGSI

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Human Genome Sciences, Inc. (NGM:HGSI) Delayed quote data

Last Trade:	27.92 USD
Trade Time:	Nov 24
Change:	0.00 (0.00%)
Prev Close:	27.92
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	32.07

Day's Range:	N/A - N/A
52wk Range:	0.45 - 29.48
Volume:	0
Avg Vol (3m):	8,447,920
Market Cap:	4.61B
P/E (ttm):	N/A
EPS (ttm):	-0.16
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add HGSI to Portfolio

Download Data

HEADLINES

•	Best Performing U.S. Stocks Year to Date
	at Seeking Alpha (Tue 2:32pm)

•	Signals Favor a Santa Claus Rally
	at Minyanville.com (Tue 2:20pm)

•	Wall Street's Buy List
	at Motley Fool (Tue 12:38pm)

•	Human Genome Sciences and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Lymphoid Tumors
	Business Wire (Mon, Nov 23)

•	What to Do When the Dow Hits 7,500 Again
	at Motley Fool (Sat, Nov 21)

•	Credit Cards Party, Bears Smell Blood At E*Trade
	at Forbes.com (Thu, Nov 19)

•	Lightning Round OT: Anheuser-Busch, Human Genome Sciences and More
	at CNBC (Wed, Nov 18)

•	UPDATE - Icelandic gene pioneer Decode files for bankruptcy
	at Reuters (Tue, Nov 17)

•	Human Genome's ABthrax Faces FDA Delay
	Zacks.com (Tue, Nov 17)

•	BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
	at Seeking Alpha (Tue, Nov 17)

•	FDA requests more details on HGSI anthrax drug
	at bizjournals.com (Mon, Nov 16)

•	US stocks rise on recovery hopes
	at FT.com (Mon, Nov 16)

•	Direction of Cholesterol Debate Could Benefit Abbott Labs
	at Seeking Alpha (Mon, Nov 16)

•	UPDATE - FDA denies approval for Human Genome's anthrax drug
	at Reuters (Mon, Nov 16)

•	Human Genome sees FDA delay with anthrax treatment
	AP (Mon, Nov 16)

More Headlines for HGSI...

ANALYST

EPS Est (next year) (Dec-09) :	0.03
EPS Est (in 2 years) (Dec-10) :	-0.51
Avg Rec (current)*:	1.7
PEG Ratio:	182.53

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The companys clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer.

Full Company Profile

Add to Portfolio

Email to a Friend

•